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OPEN
ARTICLE
Rap1-mediated nuclear factor-kappaB (NF-κB) activity
regulates the paracrine capacity of mesenchymal stem cells in
heart repair following infarction
Y Zhang1, S Chiu1, X Liang1, F Gao3, Z Zhang3, S Liao1, Y Liang1, Y-H Chai1, DJH Low4, H-F Tse1,2, V Tergaonkar4 and Q Lian1,2,3,5
Paracrine effect is the major mechanism that underlies mesenchymal stem cells (MSC)-based therapy. This study aimed to examine
how Rap1, telomeric repeat-binding factor 2-interacting protein 1 (Terf2IP), which is a novel modulator involved in the nuclear
factor-kappaB (NF-κB) pathway, regulates the paracrine effects of MSC-mediated heart repair following infarction. NF-κB activity of
stromal cells was increased by Rap1 as measured by pNF-κB-luciferase reporter activity, and this was abolished by IkB-dominant-
negative protein. Knockdown of Rap1 with shRap1 resulted in diminished translocation of p65-NF-κB from the cytoplasm to nuclei
in response to tumor necrosis factor-α (TNF-α) stimulation. Compared with BM-MSCs, Rap1− /−-BM-MSCs displayed a signiﬁcantly
reduced ratio of phosphorylated NF-κB to NF-κB-p65 and of Bax to Bcl-2, and increased resistance to hypoxia-induced apoptosis by
the terminal deoxynucleotidal transferase-mediated dUTP nick end labeling (TUNEL) assay. In contrast, re-expression of Rap1 in
Rap1− /−-BM-MSCs resulted in loss of resistance to apoptosis in the presence of hypoxia. Moreover, absence of Rap1 in BM-MSCs led
to downregulation of NF-κB activity accompanied by reduced pro-inﬂammatory paracrine cytokines TNF-α, IL (interleukin)-6 and
monocyte chemotactic protein-1 in Rap1− /−-BM-MSCs compared with BM-MSCs. The apoptosis of neonatal cardiomyocytes
(NCMCs) induced by hypoxia was signiﬁcantly reduced when cocultured with Rap1− /−-BM-MSC hypoxic-conditioned medium
(CdM). The increased cardioprotective effects of Rap1− /−-BM-MSCs were reduced when Rap1− /−-BM-MSCs were reconstituted with
Rap1 re-expression. Furthermore, in vivo study showed that transplantation of Rap1− /−-BM-MSCs signiﬁcantly improved heart
function, decreased infarct size, prevented cardiomyocyte apoptosis and inhibited inﬂammation compared with controls and
BM-MSCs (Po0.01). This study reveals that Rap1 has a critical role in the regulation of MSC paracrine actions. Compared with
BM-MSCs, Rap1− /−-BM-MSCs decreased NF-κB sensitivity to stress-induced pro-inﬂammatory cytokine production and reduced
apoptosis. Selective inhibition of Rap1 in BM-MSCs may be a novel strategy to enhance MSC-based therapeutic efﬁcacy in
myocardial infarction.
Cell Death Discovery (2015) 1, 15007; doi:10.1038/cddiscovery.2015.7; published online 24 August 2015
INTRODUCTION
Recent developments in stem cell biology to prevent or treat heart
failure have moved from experimental research to clinical trials
using different types of adult stem cells, such as adult bone
marrow stem cells or mesenchymal stem cells (MSCs).1,2
Despite the promising results observed in preclinical and clinical
studies, the potential mechanisms underlying stem cell-based
therapy have not been fully classiﬁed. Accumulating evidence
demonstrates that apart from transdifferentiation, it is the
paracrine effects of MSCs that are predominately responsible for
cardiac repair.3 Indeed, the exact extent to which these cells
transdifferentiate into new cardiomyocytes to improve heart
function remains highly controversial.4,5 There is increasing
recognition that MSCs produce a variety of cytokines that can
directly promote cell survival and regulate inﬂammation following
myocardial infarction (MI).3,6 Various cytokines and growth factors
have been investigated in different tissue-derived MSCs.7,8 Some
cytokines and growth factors have been shown to be critical for
cardiac protection, for example, basic ﬁbroblast growth factor,
vascular endothelial growth factor, stromal-derived factor,9,10
secreted frizzled related protein,11 interleukin-10 (IL-10)12 and
metalloproteinase-9.13 In contrast, some cytokines and factors
produced from MSCs, including tumor necrosis factor-α (TNF-α)
and interleukin-6 (IL-6),14 are harmful for heart recovery. As a
result, injection of MSCs or total MSC paracrine factors without
optimization may limit their therapeutic efﬁcacy. Therefore,
optimization of MSCs before transplantation to maximize cell
survival and beneﬁcial paracrine factors is important. Nevertheless,
the potential mechanism underlying regulation of MSC secretion
is poorly understood and identiﬁcation of the key molecules that
govern MSC secretion to protect against heart ischemia injury
remains urgently to be addressed.
Rap1 (Trf2IP), a telomeric repeat-binding factor 2-interacting
protein 1 (Terf2IP), is a novel modulator involved in the Nuclear
factor-kappaB (NF-κB) pathway.15,16 Many telomeric proteins apart
from Rap1 including telomerase are now known to regulate
inﬂammation through NF-κB signaling.17,18 It has been documen-
ted that NF-κB family factors have important roles in the
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regulation of mitochondrial ROS/bioenergy, DNA replication, cell
survival and inﬂammation in many cell types,19–22 including
MSCs.23 Prior studies have also demonstrated that NF-κB
activation mediates cytokine/growth factor secretion by MSCs.24
Given the multifaceted effects of NF-κB activity on MSCs, efforts to
identify important regulators (s) that modulate speciﬁcity in the
functioning of the NF-κB signal pathway is a major challenge. Use
of a genetic engineering will provide a greater understanding of
the roles and mechanisms of speciﬁc factors that modulate NF-κB
activation in MSC-mediated cardioprotection. It also has been
reported that MSCs can secrete a variety of cytokines to regulate
inﬂammation and enable cardiac repair posttransplantation.25
Hence, to determine whether Rap1 can regulate MSC paracrine
factors, which thereby impinges on cardiac repair, we designed
this study. In this study, we proposed that inhibition of Rap1 can
decrease pro-inﬂammatory factors secreted by MSCs, enhance cell
survival and thus improve its therapeutic effects in MI. In this
study, we showed that Rap1− /−-BM-MSCs have a better ther-
apeutic efﬁcacy than wild-type (WT) BM-MSCs for cardiac
repair post MI in mice. The greater therapeutic potential of
Rap1− /−-BM-MSCs for cardiac repair is not only attributed to the
higher cell survival post-transplantation, but also to a reduced
secretion of pro-inﬂammatory cytokines. Our results may prompt
the development of new therapeutic strategies to enhance MSC-
based therapy in MI.
RESULTS
Characterization of BM-MSCs and Rap1− /− -BM-MSCs
As shown in Figure 1a, FACS analysis demonstrated that control
BM-MSCs and Rap1− /−-BM-MSCs have similar surface markers that
are deﬁned in BM-MSCs, that is, Sca (+), CD90 (+), CD105 (+), CD45
(− ) and CD34 (− ; Figure 1a). Oil red staining showed that
adipogenesis was highly observed in 480% of BM-MSCs and
Rap1− /−-BM-MSCs (Figure 1bi). Alcian Blue staining showed that
chondrogenesis was efﬁcient with 480% cells for calcium
deposition (Figure 1bii). Alizarin Red staining revealed that
BM-MSCs and Rap1− /−-BM-MSCs could differentiate into osteo-
genic cells (Figure 1biii). In addition, western blot analysis
showed that Rap1 was detected in BM-MSCs, but not in
Rap1− /−-BM-MSCs (Figure 1c), indicating the total deletion of
Rap1 from Rap1− /−-BM-MSCs.
Activation of NF-κB transcriptional activity by Rap1
In order to address the direct relationship between NF-κB and
Rap1, the activation of NF-κB transcriptional activity by Rap1 was
examined. A reporter gene construct carrying NF-κB-Luc was used
to report NF-κB activity. This construct contains an NF-κB enhancer
element located upstream of the secreted luciferase gene. Binding
of transcription factors to the NF-κB enhancer element allows
luciferase (tLuc) to be expressed and secreted into the surrounding
medium (Catalog No. 631743; Clontech Laboratories, Mountain
View, CA, USA). As shown in Figure 2a, HeLa cells were transfected
with indicated plasmids. Groups i and iii received WT reporter
constructs p NF-κB-Luc, whereas group ii received delta NF-κB-Luc.
All groups received pSV-RLuc. The amount of expression plasmid
for Rap1 (i and ii) and IkB-dominant-negative (iii) was progressively
increased as indicated. Relative luciferase activity represents ﬁreﬂy
luciferase activity recovered from pNF-κB-Luc or pdelta κB-Luc
normalized to Renilla luciferase activity recovered from pSV-RLuc
(Figure 2a). The results presented showed that the activity of
NF-κB transcriptional activity was activated by Rap1.
Next, the relationship of IKKγ and Rap1 was examined. As
shown in Figure 2b, HEK293T cells were transfected with
expression plasmids for Flag-tagged Rap1 (lanes 3 and 4),
HA-tagged IKKγ (lanes 2 and 4). All groups received His-tagged
ubiquitin expression plasmid. His-tagged ubiquitin conjugates
were pulled down. The ubiquitinated Rap1 and IKKγ were
detected using western blot analysis with anti-Flag (Figure 2bi)
and anti-HA (Figure 2biii), respectively. The input lysates were also
probed for anti-Flag and anti-HA to detect Rap1 and IKKγ,
respectively (Figure 2bii and iv). These results show the IKKγ-
mediated ubiquitination of Rap1.
Immunostaining results demonstrated that NF-κB translocated
from the cytoplasm to nuclei when HeLa cells were stimulated
with TNF-α (Figure 2ci and ii). Nonetheless, translocation of
NF-κB-p65 from the cytoplasm to nuclei responding to TNF-a
stimulation was diminished by knocking down Rap1 with shRap1
(Figure 2ciii and iv). These results show that the absence of Rap1
negatively regulates activation of NF-κB.
Rap1− /−-BM-MSCs are more tolerant than BM-MSCs
to hypoxia-induced apoptosis
Apoptosis of Rap1− /−-BM-MSCs and BM-MSCs under normoxic or
hypoxic conditions was examined. As shown in Figures 3a and b,
the apoptotic rate of Rap1− /−-BM-MSCs and BM-MSCs under
normoxia was similar and very low (Figure 3b, 2.55 ±0.59%
versus 1.7 ± 0.52%; P40.05). Nonetheless, compared with
normoxia, the apoptotic rate was signiﬁcantly increased under
hypoxic conditions. Notably, compared with BM-MSCs, the
apoptotic rate of Rap1− /−-BM-MSCs under hypoxia was much
lower (Figure 3b, 17.7 ± 1.2% versus 8.1 ± 0.87%; Po0.01),
suggesting that Rap1− /−-BM-MSCs have superior resistance to
the challenge of hypoxia.
As shown in Figure 3c, western blot analysis results demon-
strated that hypoxia signiﬁcantly increased the ratio of p-NF-κB/
NF-κB-p65 and the ratio of Bax/Bcl-2 in Rap1− /−-BM-MSCs and BM-
MSCs. Notably, compared with BM-MSCs, NF-κB activation and the
levels of Bax/Bcl-2 were greatly reduced in Rap1− /−-BM-MSCs
under conditions of hypoxia (Figure 3c).
To further understand the role of Rap1 in the regulation of MSCs
against hypoxia, deﬁciency of Rap1− /−-BM-MSCs was replenished
with Rap1 re-expression using a lentivirus system. As shown in
Figure 3di, Rap1 was detected in Rap1-Rap1− /−-BM-MSCs but not
in Rap1− /−-BM-MSCs. Under hypoxic challenge, apoptosis of Rap1-
Rap1− /−-BM-MSCs was much higher than Rap1− /−-BM-MSCs
(Figure 3dii and iii; Po0.01). These results further conﬁrm that
deletion of Rap1 increases the resistance of MSCs to the challenge
of hypoxia.
CdM of Rap1− /−-BM-MSCs alleviates hypoxia-induced NCMC
apoptosis
The pro-inﬂammatory factors from Rap1− /−-BM-MSCs and BM-
MSC-CdM under normoxic and hypoxic conditions were exam-
ined. As shown in Figure 4ai, ii and iii, compared with the
normoxia-CdM (conditioned medium), the concentration of TNF-α,
IL-6 and monocyte chemotactic protein 1 (MCP-1) was increased
in hypoxia-CdM of Rap1− /−-BM-MSCs and BM-MSCs. Furthermore,
in the hypoxia-CdM, the concentration of TNF-α, IL-6 and MCP-1
was much lower in the Rap1− /−-BM-MSC group than in the
BM-MSC group (Figure 4a, Po0.01). Notably, the concentration
of TNF-α, IL-6 and MCP-1 was also increased in Rap1-Rap1− /−-BM-
MSC-hy-CdM compared with Rap1− /−-BM-MSC-hy-CdM, indicating
that deletion of Rap1 reduces pro-inﬂammatory factor release by
MSCs (Figure 4a).
Next, in order to examine the protective effects of MSC-hypoxia-
CdM, neonatal cardiomyocytes (NCMCs) were divided into ﬁve
groups and received the following different treatments: (1) control
group; (2) 50 μl serum- and antibiotic-free DMEM (Dulbecco’s
modiﬁed Eagle’s medium; hypoxia group); (3) 50 μl BM-MSCs
hypoxia-CdM (BM-MSC-hy-CdM group); (4) 50 μl Rap1− /−-BM-MSC
hypoxia-CdM (Rap1− /−-BM-MSC-hy-CdM group); and (5) Rap1-
Rap1− /−-BM-MSC hypoxia-CdM (Rap1-Rap1− /−-BM-MSC-hy-CdM
group) and then cultured for 48 h under hypoxia. Then terminal
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deoxynucleotidal transferase-mediated dUTP nick end labeling
(TUNEL) assay was performed to examine apoptosis in the
different groups. As shown in Figures 4b and c, the apoptotic
rate of NCMCs in the hypoxia group was dramatically increased
compared with the control group (Po0.01). In contrast, the
apoptotic rate in Rap1− /−-BM-MSC-hy-CdM-, BM-MSC-hy-CdM- and
Rap1-Rap1− /−-BM-MSC-hy-CdM-treated groups was signiﬁcantly
decreased compared with the hypoxia group (Po0.01). In
addition, the apoptotic rate in the Rap1− /−-BM-MSC-hypoxia-
CdM-treated group was lower than that in the BM-MSC-hypoxia-
CdM-treated group (Po0.01). Notably, the apoptotic rate was
signiﬁcantly increased in the Rap1-Rap1− /−-BM-MSC-hy-CdM
Figure 1. Characterization of BM-MSCs and Rap1− /−-BM-MSCs. (a) Surface markers proﬁling determined with FASC that is positive for Sca-1,
CD90 and CD105; negative for CD34 and CD45. (b) (i) Oil red staining for adipogenesis. (ii) Alcian blue staining for chondrogenesis. (iii) Alizarin
red staining for osteogenesis. (c) Expression of Rap1 in BM-MSCs and Rap1− /−-BM-MSCs.
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group compared with the Rap1− /−-BM-MSC-hy-CdM group,
indicating that increased Rap1 can downregulate the cardiopro-
tection of Rap1− /−-BM-MSCs by regulating the paracrine effects
(Figures 4b and c).
Transplantation of Rap1− /−-BM-MSCs enhances cell survival and
cardioprotection in MI
Invasive hemodynamic measurement at 4 weeks post-cell transplan-
tation showed that, compared with the MI group, left ventricle end
systolic pressure (LVESP), maximum dp/dt and slope of end systolic
pressure volume relationship (ESPVR) were signiﬁcantly increased
(Figures 5a and b; Po0.01) in the MSC transplantation groups.
Furthermore, LVESP, maximum dp/dt and slope of ESPVR were
signiﬁcantly higher in the Rap1− /−-BM-MSCs group than in the BM-
MSCs group (Figures 5a and bi, ii and iii; Po0.01).
Cardiac ﬁbrosis was assessed using Masson Trichrome staining
(Figure 5c). At 4 weeks post-MSC transplantation, cardiac ﬁbrosis
was signiﬁcantly reduced by 28.1% in the BM-MSCs group and by
68.2% in the Rap1− /−-BM-MSCs group, compared with the MI
group (Figure 5d; Po0.01). Compared with the BM-MSCs group,
the extent of cardiac ﬁbrosis was also signiﬁcantly lower in the
Rap1− /−-BM-MSCs group (Figure 5d, 31.2 ± 5.4% versus
13.8 ± 3.3%; Po0.01).
Before cell transplantation, MSCs were labeled with Qtracker.
The engrafted MSCs at 4 weeks post-transplantation in the
ischemic myocardium were visualized and quantiﬁed. Both BM-
MSCs and Rap1− /−-BM-MSCs were successfully engrafted in the
ischemic heart tissue (Figure 5e). Notably, the number of Qtracker-
positive cells that survived in the ischemic myocardium 4 weeks
posttransplantation was much higher in the Rap1− /−-BM-MSCs
group than in the BM-MSCs group (Figure 5ﬁ, 36.6 ± 6.4/20 ×
versus 16.6 ± 4.5/20 × ; Po0.01). Immunostaining with troponin
showed that some Qtracker-positive cells in the ischemic
myocardium differentiated into cardiomyocytes (Figure 5e).
Nevertheless, only a small proportion of retained BM-MSCs
(~4.9%) and Rap1− /−-BM-MSCs (~5.3%) had transdifferentiation
or cell fusion to cardiomyocytes (Figure 5f ii).
Figure 2. Activation of NF-κB transcriptional activity by Rap1. (a) HeLa cells were transfected with indicated plasmids. Groups i and iii received
WT reporter constructs p NF-κB-Luc, whereas group B received delta NF-κB-Luc. All groups received pSV-RLuc. The amounts of expression
plasmid for Rap1 (i and ii) and IkB-dominant-negative (iii) were progressively increased as indicated. Relative luciferase activity (RLA)
represents ﬁreﬂy luciferase activity recovered from pNF-κB-Luc or p delta κB-Luc normalized to Renilla luciferase activity recovered from
pSV-RLuc. (b) HEK293T cells were transfected with expression plasmids for Flag-tagged Rap1 (lanes 3 and 4) and HA-tagged IKKγ (lanes 2
and 4). All groups received His-tagged ubiquitin expression plasmid. His-tagged ubiquitin conjugates were pulled down. The ubiquitinated
Rap1 and IKKγ was detected using western blot analysis with anti-Flag (i) and anti-HA (ii), respectively. The input lysates were also probed for
anti-Flag and anti-HA to detect Rap1 and IKKγ, respectively (ii and iv). (c) Representative photographs show the location of NF-κB-p65 in
HeLa cells (i) and shRap1-transfected HeLa cells (iii). NF-κB-p65 was translocated from the cytoplasm to nuclei responding to TNF stimulation
(ii). Knocking down Rap1 with shRap1 resulted in diminished translocation of NF-κB-p65 from the cytoplasm to nuclei responding to
TNF stimulation (iv).
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Figure 3. Rap1− /−-BM-MSCs are more tolerant than BM-MSCs against hypoxia challenge. (a) Representative images show apoptosis of
BM-MSCs and Rap1− /−-BM-MSCs under normoxia and hypoxia. (b) The apoptotic rate was quantitatively measured in BM-MSCs and
Rap1− /−-BM-MSCs under normoxia and hypoxia (*Po0.01). (c) (i) Western blot analysis shows the expression of p-p65-NF-κB, p65-NF-κB, Bcl-2
and Bax of BM-MSCs and Rap1− /−-BM-MSCs under normoxia and hypoxia. (ii) Quantitative measurement of pNF-κB-p65/NF-κB-p65 of
BM-MSCs and Rap1− /−-BM-MSCs under normoxia and hypoxia after normalized to β-actin (*Po0.01). (iii) Quantitative measurement of
Bax/Bcl-2 of BM-MSCs and Rap1− /−-BM-MSCs under normoxia and hypoxia (*Po0.01). (d) (i) Western blot analysis shows overexpressed
Rap1 in Rap1− /−-BM-MSCs. (ii) Representative images show apoptosis of Rap1− /−-BM-MSCs and Rap1-Rap1− /−-BM-MSCs under hypoxia. White
arrows denote apoptotic cells. (iii) The apoptotic rate was quantitatively measured in Rap1− /−-BM-MSCs and Rap1-Rap1− /−-BM-MSCs under
hypoxia (*Po0.01). All graphs represent the mean and error bars represent S.D. Data are representative of at least three independent
experiments.
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Rap1− /−-BM-MSCs transplantation reduces cardiomyocyte
apoptosis linked to increased angiogenesis and decreased
inﬂammation in vivo
As shown in Figures 6a and b, compared with the control
group, apoptosis of cardiomyocytes was signiﬁcantly increased
in the MI group (Figures 6a and b, 23.3 ± 3.3% versus 1.5 ± 0.4%;
Po0.01). Transplantation of BM-MSCs or Rap1− /−-BM-MSCs
signiﬁcantly decreased the cardiomyocyte apoptotic rate
(Figures 6a and b; Po0.01). In addition, the apoptotic rate in
the Rap1− /−-BM-MSC group was much lower than in the
Figure 4. Distinct paracrine effects of BM-MSCs, Rap1− /−-BM-MSCs and Rap1-Rap1− /−-BM-MSCs. (a) The expression of TNF-α, IL-6 and MCP-1
of BM-MSCs, Rap1− /−-BM-MSCs and Rap1-Rap1− /−-BM-MSCs under normoxia and hypoxia (*Po0.01). (b) Representative images show
apoptosis of NCMCs cocultured with the hypoxia-CdM from BM-MSCs, Rap1− /−-BM-MSCs and Rap1-Rap1− /−-BM-MSCs under hypoxic
condition. White arrows denote the apoptotic cells. (c) The apoptotic rate of NCMCs was measured among the different experimental groups
(*Po0.01 versus the control group; #Po0.01 versus the hypoxia group; †Po0.01 versus the BM-MSCs-hy-CdM group; $Po0.01 versus the
Rap1− /−-BM-MSCs-hy-CdM group). All graphs represent the mean and error bars represent S.D. Data are representative of at least three
independent experiments.
Figure 5. Rap1− /−-BM-MSC transplantation restores heart function, reduces infarction size and increases cell survival in mice of the MI group.
(a) Cardiac catheterization shows BM-MSC or Rap1− /−-BM-MSC transplantation-restored LV function at 4 weeks after cell transplantation.
(b) LVESP (i), +dp/dt (ii) and slope of ESPVR (iii) were quantitatively measured among the different experimental groups (*Po0.01 versus the
control group; #Po0.01 versus the MI group; †Po0.01 versus the BM-MSC group). (c) Representative images show at 4 weeks post-cell
transplantation, MSC transplantation reduced the infarction size. (d) Fibrosis formation was measured in heart tissue among different
experimental groups (*Po0.01 versus the MI group; #Po0.01 versus BM-MSC group). (e) At 4 weeks post-cell transplantation, Qtracker-positive
cells in the heart tissue were detected in BM-MSC or Rap1− /−-BM-MSC group. Moreover, some Qtracker-positive cells also coexpressed
troponin, suggesting some grafted MSCs differentiated into cardiomyocytes. (f) (i) Qtracker-positive cell in the heart tissue was quantitatively
measured in BM-MSC- or Rap1− /−-BM-MSC-treated mice (*Po0.01 versus BM-MSC group). (ii) The ratio of Qtracker-positive and troponin-
positive cells to Qtracker-positive cell as percent of cell differentiation in BM-MSC- or Rap1− /−-BM-MSC-treated mice was calculated. All graphs
represent the mean and error bars represent S.D. Data are representative of at least three independent experiments.
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BM-MSC group (Figures 6a and b, 15.3 ± 2.1% versus 8.8 ± 1.5%;
Po0.01).
The capillary density of the MI area was evaluated by
PECAM (CD31) staining. Compared with the control group, the
capillary density was dramatically reduced in the MI group
(Figure 6ci and ii, 71.7 ± 9.7/20 × versus 19.6 ± 7.9/20 × ; Po0.01).
Transplantation of BM-MSCs or Rap1− /−-BM-MSCs signiﬁcantly
increased the capillary density of the MI area (Figure 6ci and ii;
Rap1-mediated MSC therapy for heart repair
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Figure 6. Rap1− /−-BM-MSC transplantation ameliorates cardiomyocyte apoptosis, enhances angiogenesis and reduces inﬂammation in the
mice of the MI group. (a) Representative images show apoptosis of cardiomyocytes at 4 weeks post-cell transplantation in the heart tissue
of MI. (b) The apoptotic rate was measured in heart tissue of different experimental groups. (c) Representative images show the capillaries
(i) and blood vessels (iii) in the heart tissue at 4 weeks post-cell transplantation. (ii) The density of CD31 was measured in heart tissue among
different experimental groups. (iv) The blood vessels in the heart tissue among the different groups were measured (*Po0.01 versus the
control group; #Po0.01 versus the MI group; †Po0.01 versus the BM-MSC group). (d) (i) Representative images show inﬂammatory inﬁltration
mononuclearcyte CD45 cells accumulated in the heart tissue among different groups. (ii) The inﬂammation in the different groups was
measured as percent of CD45-positive staining cells versus DAPI-positive cells per myocardium area. (iii) The concentration of TNF-α among
different groups was measured (*Po0.01 versus the control group; #Po0.01 versus the MI group; †Po0.01 versus the BM-MSCs group).
All graphs represent the mean and error bars represent S.D. Data are representative of at least three independent experiments.
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Po0.01), and the capillary density in the Rap1− /−-BM-MSC group
was much higher than in the BM-MSC group (Figure 6ci and ii,
51 ± 6.6/20 × versus 36.7 ± 5.8%; Po0.01).
The blood vessels of the MI area were evaluated by smooth
muscle actin (SMA) staining; blood vessels were greatly increased
in the BM-MSC and Rap1− /−-BM-MSC groups compared with the
MI group (Figure 6ciii and iv; Po0.01). Moreover, blood vessel
density was much higher in the Rap1− /−-BM-MSC group than in
the BM-MSC group (Figure 6ciii and iv, 6.4 ± 1.1/20 × versus
3.8 ± 0.8/20 × ; Po0.01).
One week post-cell transplantation, inﬂammation in heart tissue
among the different experimental groups was evaluated by CD45
staining and ELISA. As shown in Figure 6di and ii, inﬂammation in
the MI group was dramatically increased compared with the
control group (Figure 6di and ii, 37.3 ± 5.6% versus1.2 ± 0.6%;
Po0.01). Transplantation of BM-MSCs or Rap1− /−-BM-MSCs
signiﬁcantly decreased this inﬂammation (Figure 6di and ii;
Po0.01). The inﬂammation in the Rap1− /−-BM-MSC group was
much lower than that in the BM-MSC group (Figure 6di and ii,
25.8 ± 3.3% versus 13± 4.5%; Po0.01).
Similar results were seen in the measurement of TNF-α using
ELISA in the different groups. Nonetheless, as shown in
Figure 6diii, 1 week following MSC transplantation, TNF-α
was markedly reduced by 31.3 and 53.6% in the BM-MSC and
Rap1− /−-BM-MSCs groups, respectively, compared with the
MI group (Figure 6d and iii; Po0.01). In addition, TNF-α in
Rap1− /−-BM-MSCs was much lower than in BM-MSCs (Figure 6diii,
33.3 ± 4.5 versus 21.8 ± 2.7 pg/mg; Po0.01).
DISCUSSION
There are several major ﬁndings in this study. First, Rap1− /−-BM-
MSCs were more tolerant than BM-MSCs to hypoxia that is
associated with reduced activation of NF-κB activity. Second,
compared with BM-MSCs, Rap1− /−-BM-MSCs showed a better
therapeutic efﬁcacy in MI. Third, Rap1− /−-BM-MSC-mediated
cardiac repair was associated with reduced inﬂammation post
MI and enhanced cell survival. Finally, secretion proﬁling revealed
reduced pro-inﬂammatory cytokines in Rap1− /−-BM-MSCs such as
TNF-α, IL-6 and MCP-1.
NF-κB has been documented as a pro- or anti-apoptotic gene
that depends on the cellular context26–28 and which upstream
signaling it is activated by. NF-κB is also essential for the survival of
many cells and functional response to stress.23 In endothelial cells,
inhibition of NF-κB activity signiﬁcantly attenuates apoptosis
induced by hypoxia.29 In this study, under hypoxic conditions,
apoptosis of Rap1− /−-BM-MSCs was much lower than that of
BM-MSCs because of inhibition of NF-κB activity and Bax/Bcl-2,
and was conﬁrmed using the western blot analysis. The Rap1 gene
is a novel adaptor that regulates NF-κB activity by serving as the
adaptor of the IKK complex, having a critical role in regulating cell
apoptosis15 and metabolism.30 In this study, we showed that
absence of Rap1 negatively regulated the activation of NF-κB in
MSC. Our data also demonstrated that deletion of Rap1 in MSCs
inhibits the activation of NF-κB, reduces the ratio of Bax/Bcl-2 and
then directly attenuates the apoptosis induced by hypoxia,
suggesting that inhibition of Rap1 enhances MSC survival
capacity under hypoxia. These results prompt us to consider
Rap1− /−-BM-MSC transplantation instead of BM-MSCs for MI in
that Rap1− /−-BM-MSCs have a stronger ability to survive in the
hostile environment of the injured heart. In our in vivo study, we
conﬁrmed that 4 weeks after transplantation, more Rap1− /−-BM-
MSCs than BM-MSCs survived and contributed more to the
recovery of heart function.
NF-κB activation enhances expression of pro-inﬂammatory
cytokines such as IL-6, IL-8 and TNF-α, and then provokes an
excessive inﬂammatory response, with detrimental consequences.31,32
Total inhibition of NF-κB leads to cell functional defects.33
Selective inhibition of certain signals to reduce NF-κB activity
has been proposed as a novel therapeutic strategy in many
inﬂammatory diseases and cancer treatment.34,35 Previous studies
have revealed that MSCs have contradictive effects with pro-
and anti-inﬂammatory properties.36 Enhancement of the anti-
inﬂammatory effects of MSCs would be important to increase the
efﬁcacy of cardiovascular repair.37,38 Thus, deletion of Rap1 can
regulate NF-κB activation, thereby mediating pro- and anti-
inﬂammatory cytokine release. Our data demonstrated that, under
hypoxia, the expression of pro-inﬂammatory cytokines IL-6, TNF-α
and MCP-1 in the Rap1− /−-BM-MSCs was much lower than in BM-
MSC CdM. This suggests that the absence of Rap1 reduces NF-κB
activation and decreases the pro-inﬂammatory cytokine produc-
tion by MSCs. Furthermore, hypoxia-CdM from Rap1− /−-BM-MSCs
demonstrated a superior protective effect to BM-MSCs against
myocardial death under hypoxia challenge, indicating that the
beneﬁcial paracrine function is enhanced in Rap1− /−-BM-MSCs
compared with WT MSCs. To further conﬁrm the key role of Rap1
in regulating pro-inﬂammatory cytokine release by MSCs, we
transfected Rap1− /−-BM-MSCs with Rap1; when Rap1− /−-BM-
MSCs overexpressed Rap1, the expression of IL-6, TNF-α and
MCP-1 was elevated under hypoxic conditions, suggesting that
deletion of Rap1 has a strong capacity to regulate the paracrine
action of MSCs.
There are some aspects of this study that need further
investigation. First, the secretion of MSCs in the ischemic heart
may differ under in vitro hypoxia. Second, apart from the anti-
inﬂammatory reaction of MSCs in this study, many other potential
mechanisms of MSCs need to be further investigated. Third,
whether deletion of Rap1 can inﬂuence other potential signaling
pathways to mediate MSC-based therapy for cardiovascular
disease also needs further investigation.
In summary, in this study we established that a novel NF-κB
adaptor, Rap1, has an important role in the regulation of MSC
paracrine components and MSC capacity for survival in a stressful
environment. Compared with WT BM-MSCs, transplantation of
Rap1− /−-BM-MSCs achieved superior therapeutic efﬁcacy in a
mouse model of MI that may be attributed to Rap1-modulated
cytokine bias and cell survival potential.
MATERIALS AND METHODS
Mice
The WT and Rap1− /− mice, provided by the National University of
Singapore, were bred and kept in the Laboratory Animal Unit at the
University of Hong Kong. All animal experiments in this study were
approved by the Committee on the Use of Live Animals in Teaching and
Research at The University of Hong Kong.
Isolation, culture and characterization of Rap1− /−-BM-MSCs
and BM-MSCs
Rap1− /−-BM-MSCs and BM-MSCs were isolated from 6~ 8-week-old
Rap1− /− and WT mice, respectively. Brieﬂy, following killing, femurs
and tibiae were quickly removed from mice and bone marrow was
harvested by strong ﬂushing with DMEM (Invitrogen) supplemented with
10% fetal bovine serum (FBS, Gibco, USA) and P/S on ice. The resultant cell
suspension was ﬁltered using a 70-mm ﬁlter and bone marrow cells were
planted in culture dishes with complete DMEM medium and incubated at
37 °C with 5% CO2 in a humidiﬁed chamber. Non-adherent cells were
removed 3 h later by replacing the culture medium. Thereafter, the culture
medium was replaced with fresh medium and the process repeated every
8 h until 72 h of initial culture was reached. MSCs were characterized using
ﬂow cytometry. Oil red staining was performed to identify adipocytes,
alcian blue staining for chondrocytes and alizarin red staining for
osteocytes. In order to track MSCs posttransplantation, MSCs were labeled
with the cell tracker dye Qtracker 655 Cell Labeling Kit (Q25021MP, Life
Technologies, Carlsbad, CA, USA) according to the manufacturer’s
instructions. The labeling efﬁciency was veriﬁed using ﬂow cytometry.
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Preparation of CdM
The CdM of cultured Rap1− /−-BM-MSCs and BM-MSCs was collected as
previously reported.39 Brieﬂy, MSCs were rypsinized and plated on a 10-cm
plate. After 24 h, the completed culture medium was replaced with serum-
and antibiotic-free DMEM. Twenty-four hours later, serum-free cell culture
supernatants were collected, ﬁltered by a 0.22-μm ﬁlter and centrifuged at
4 °C, 4000 × g for 30 min using Amicon Ultra-4 Centrifugal Filter Devices
(Millipore Billerica, MA, USA) to produce CdM. The ﬁnal concentration was
adjusted to 20× of collected CdM.
NCMC isolation and culture
The NCMCs were isolated and cultured as described previously.40 Brieﬂy,
following killing of neonatal Wistar rats (0- to 1-day-old), the hearts were
promptly removed, rinsed four times with modiﬁed Hank’s solution and
cut into small pieces on ice. The tissue fragments were transferred to
a 50-ml tube and warmed in a water bath with a magnetic bar for 10min
at 37 °C. After discarding the supernatant, the minced myocardium was
digested with fresh pre-warmed 0.25% trypsin for 5 min at 37 °C, and the
supernatant collected gently and transferred to a 50-ml tube on ice
containing 7ml FBS. These two steps were repeated to collect supernatant
after which all supernatants were centrifuged at 156.8 × g for 5 min to
collect the cells. Cells were re-suspended in NRVM culture medium to
reduce ﬁbroblast contamination. Finally, the supernatant was aspirated
gently, and the cells were plated in MEA dishes at a density of 6×05 cells/ml.
Culture medium was changed every day.
TUNEL assay
To directly visualize apoptosis of MSCs exposed to hypoxia and the NCMCs
cocultured with MSC-CdM under hypoxic conditions, TUNEL assay was
performed according to the manufacturer’s instructions. Brieﬂy, after
washing with PBS, the cells on the cover slide were incubated with 1 μg/ml
Proteinase K/10mM Tris solution at room temperature for 15min and then
washed twice in PBS and ﬁnally incubated with 50 μl TUNEL reaction
mixture in a humid chamber for 1 h at room temperature. Cover slides
were washed twice with PBS, mounted with 4, 6-diamidino-2-phenylindole
(DAPI), observed under a ﬂuorescent microscope and ﬁnally
photographed.
Western blot analysis
Total proteins were extracted from cells using RIPA buffer and the
concentration measured. Protein (20 μg) was separated in a 10% SDS-PAGE
gel and transferred on a PVDF membrane (Millipore). The membrane was
washed three times in Tris-buffered saline (TBS) with 0.1% Tween-20 and
blocked with 5% fat-free milk in TBS for 1 h at room temperature.
Subsequently, the membrane was incubated with anti-Rap1, Bcl-2,
Bax, p-NF-κB-p65 and NF-κB-p65 (Santa Cruz, Dallas, TX, USA; 1 : 2000)
overnight at 4 °C followed by incubation with horseradish peroxidase-
conjugated secondary antibodies (1 : 10 000 dilution; Santa Cruz). Finally,
the signal on the membranes was visualized using ECL and exposed to
medical X-ray ﬁlms for seconds or minutes.
Lentiviral construct packaging and infection
The lentivirus was packaged by co-transfecting 293T cells using the
lentiviral packaging system comprising the recombinant lentiviral transfer
Rap1 plasmid or shRap1 plasmid, packaging (GAG/Pol and REV) plasmids
and envelope (VSV-G) plasmid. Following 48-h culture, the supernatant
of transfecting 293T cells was collected, concentrated and tittered.
Subsequently, the virus was used to infect Rap1− /−-BM-MSCs or HeLa cells.
MI model and cell transplantation
A MI model was induced in ICR mice (6 ~ 8-week-old). Mice were
anesthetized with an intraperitoneal injection of ketamine (100mg/kg)
and xylazine (20 mg/kg) and connected to a ventilator via tracheal
intubation. The heart was exposed via a left side limited thoracotomy and
the middle of the left anterior descending artery (LAD) ligated with an 8-0
silk suture. At 60min after induction of MI, mice were randomized to
receive intramyocardial injection of (1) PBS (MI group, n= 12); (2) 1.0 × 106
BM-MSCs (BM-MSC group, n= 13); or (3) 1.0 × 106 Rap1− /−-BM-MSCs
(Rap1− /−-MSC group, n=12) at four sites in the border of the infarct area.
Another group of mice (n= 10) underwent thoracotomy without LAD
ligation and served as controls (Control group).
Hemodynamic assessment
At 4 weeks post-cell transplantation, mice were anesthetized and
mechanically ventilated as described above. A 1.2-F pressure–volume
conductance catheter connected to an ADVantage PV-Loop system
(Scisence Inc., Ontario, Canada) for data acquisition was inserted into the
LV cavity through the right carotid artery. Hemodynamic parameters,
including LVESP and dp/dtmax, were recorded and analyzed using the
LabScribe software (Scisence Inc.). The slope of the ESPVR was measured to
evaluate heart function.
Assessment of ﬁbrosis and apoptosis
Following hemodynamic assessment, mice were killed for histological and
immunohistochemical study. Hearts were quickly taken out, washed with
cold PBS and ﬁxed in formalin for 24 h. Hearts were then embedded in
parafﬁn and cut into 5-μm sections from the apex, mid-LV. Fibrosis in the
different experimental groups was analyzed using a Masson’s Trichrome
Stain Kit (HT15, Sigma, St. Louis, MO, USA). The percentage infarct size was
calculated as (ﬁbrosis area/total LVA) × 100%. Apoptosis was evaluated
with TUNEL staining as previously described.
Immunohistochemical staining
Immunohistochemical staining was performed according to the standard
protocol. Following incubation with 5% bovine serum albumin for 30min,
heart sections or cells were stained with primary antibody and incubated
overnight at 4 °C with a 1 : 100 dilution. The antibodies were anti-Troponin
(SC-8121, Santa Cruz), anti-α-SMA (SC-53142, Santa Cruz), anti-CD31
(SC-31054, Santa Cruz) and anti-CD45 (SC-25590, Santa Cruz). Sections
were incubated with PBS instead of the primary antibody to serve as a
negative control. Then, the second antibody with FITC-conjugated anti-
mouse IgG (1 : 1000), anti-rat IgG (1 : 1000) or anti-goat IgG (1 : 1000) was
added and incubated for 1 h at room temperature. Finally, heart sections
were washed with PBS twice and mounted with 4, 6-diamidino-2-
phenylindole (DAPI) to stain the nucleus. Six mice from each group were
analyzed; ﬁve sections were randomly collected from each mouse and
then analyzed with a deconvoluted ﬂuorescent microscope and Image J
software (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis
Data are expressed as mean± S.D. The signiﬁcant differences between
groups were analyzed with unpaired Student’s t-test for two groups or
one-way ANOVA, followed by Bonferroni test for more than two groups.
A value of Po0.05 was considered statistically signiﬁcant.
ABBREVIATIONS
BM, bone marrow; CdM, conditioned medium; ESPVR, end systolic pressure
volume relationship; IL-6, interleukin-6; LVESP, left ventricle end systolic
pressure; MCP-1, monocyte chemotactic protein 1; MI, myocardial
infarction; MSCs, mensenchymal stem cells; NCMCs, neonatal cardiomyo-
cytes; NF-κB, nuclear factor-kappaB; TNF-α, tumor necrosis factor-α (TNF-α)
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